Previous Close | 72.32 |
Open | 73.53 |
Bid | 73.64 x 100 |
Ask | 74.15 x 100 |
Day's Range | 72.57 - 74.17 |
52 Week Range | 49.24 - 94.57 |
Volume | |
Avg. Volume | 179,366 |
Market Cap | 1.327B |
Beta (5Y Monthly) | 0.92 |
PE Ratio (TTM) | 24.39 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Jul 02, 2010 |
1y Target Est | N/A |
Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.
Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.
Zoetis (ZTS) reports better-than-expected first-quarter results, wherein both earnings and revenues beat estimates. Shares rise.